Andalusia Offers Free Vyjuvek for Rare Skin Disorder Patients
Andalusia has become the first Spanish region to offer Vyjuvek, a groundbreaking treatment for dystrophic epidermolysis bullosa (DEB), through its public health system. The rare genetic disorder causes severe skin fragility, leaving patients with chronic blisters and wounds from even the slightest touch. For the first time, eligible patients in the region will receive the therapy at no personal cost. DEB is a painful and incurable condition that forces sufferers like Adrian and Leo into daily wound care and repeated surgeries. Adrian has endured multiple operations, while Leo recently received his first Vyjuvek dose, describing himself as nervous but prepared.
Vyjuvek, the first drug designed specifically for DEB, works by delivering a functional copy of the defective gene directly to skin cells. However, its cost is staggering—around €100,000 per patient each month, with lifetime expenses running into millions. Despite this, Andalusia’s health service will cover the full treatment for roughly 45 eligible residents. The push for access gained momentum after DEBRA Piel de Mariposa, a patient advocacy group, collected over 150,000 signatures demanding Vyjuvek’s inclusion in Spain’s national health provisions. In February 2026, two affected families, including Leo’s, took their fight to the European Parliament. Evanina Morcillo, DEBRA’s director, called Andalusia’s move a crucial first step but stressed the need for nationwide coverage.
Andalusia’s decision marks a turning point for DEB patients, offering them access to a therapy previously out of reach due to its extreme cost. While the treatment will now be fully funded for eligible individuals in the region, advocates continue to push for broader inclusion across Spain’s public health system.
